Showing results (291-300 of 554) with videos related to
Sort By:
Pageof 56
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptorD F McDermott, E G Trehu, J W Mier, et al.AJR. American Journal of Roentgenology|June 20, 2008
Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapyAdeel Sabir, Rachel Schor-Bardach, Carol J Wilcox, et al.Thyroid : Official Journal of the American Thyroid Association|May 14, 2014
Do negative 124I pretherapy positron emission tomography scans in patients with elevated serum thyroglobulin levels predict negative 131I posttherapy scans?Gauri R Khorjekar, Douglas Van Nostrand, Carlos Garcia, et al.Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2022
The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring SteroidsNeil J Shah, Michael R Cook, Tianmin Wu, et al.JCO Oncology Practice|July 14, 2025
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint InhibitorsCharlene M Mantia, Opeyemi A Jegede, David F McDermott, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696J M Kirkwood, J Ibrahim, D H Lawson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinomaJared A Gollob, Korina G Veenstra, Robert A Parker, et al.The Oncologist|December 28, 2022
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3Luis Meza, David F McDermott, Bernard Escudier, et al.Molecular Cancer Therapeutics|August 12, 2010
Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signalingRupal S Bhatt, Xiaoen Wang, Liang Zhang, et al.BMC Microbiology|August 16, 2013
The antimicrobial lysine-peptoid hybrid LP5 inhibits DNA replication and induces the SOS response in Staphylococcus aureusSanne Gottschalk, Dan Ifrah, Sandra Lerche, et al.Pageof 56